Polymer-Stabilized Silver Nanoparticles in Wound Dressings

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Current wound dressings face challenges in effectively managing exudates and maintaining anti-microbial efficacy while being non-cytotoxic to promote healing, with silver-based dressings often precipitating and causing discoloration, and having variable safety and efficacy.

Innovation Solution

A hydrophilic porous wound dressing incorporating polymer-stabilized silver nanoparticles with a particle size of 45 nm to 85 nm, distributed uniformly throughout the substrate, in combination with polyhexamethylene biguanide (PHMB) and chlorhexidine gluconate, to provide sustained anti-microbial activity and prevent cytotoxicity.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If silver is used as an anti-microbial agent in wound dressings, then anti-microbial efficacy is improved, but cytotoxicity and precipitation causing discoloration occur

Engineering Contradiction:
Improveanti-microbial efficacyVSAvoidcytotoxicity and discoloration
Core Design Contradiction:
ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent changes the physical form of silver from bulk or coarse particles to nanoparticles with controlled size (20-100 nm), and stabilizes them through polymer coating. This parameter change at the nanoscale reduces cytotoxicity while maintaining anti-microbial efficacy, and prevents precipitation and discoloration by keeping silver in a stable colloidal form within the dressing matrix.

Inventive Principle:
Principle #35Parameter changes

Solution Approach 2:

The patent creates a composite material system combining silver nanoparticles with polymer stabilizing agents (such as polyvinylpyrrolidone or other biocompatible polymers) and incorporates them into the wound dressing matrix. This composite approach allows the silver to retain its anti-microbial properties while the polymer coating prevents aggregation, cytotoxicity, and discoloration.

Inventive Principle:
Principle #40Composite materials

2Quantity of substance

If foam dressings are used to absorb exudate, then exudate management is improved, but anti-microbial efficacy and cytotoxicity vary based on synthetic route

Engineering Contradiction:
Improveexudate absorption capacityVSAvoidanti-microbial efficacy and cytotoxicity
Core Design Contradiction:
Quantity of substanceVSReliability

Solution Approach 1:

The patent optimizes the foam structure by controlling cell size, porosity, and density parameters to enhance exudate absorption while ensuring uniform distribution and stable release of polymer-stabilized silver nanoparticles. The physical parameters of the foam are tailored to maintain anti-microbial efficacy over time without introducing cytotoxic components.

Inventive Principle:
Principle #35Parameter changes

Solution Approach 2:

The polymer-stabilized silver nanoparticles act as an intermediary carrier system within the foam matrix. The polymer coating serves as a mediator that prevents direct cytotoxic interaction with host tissues while allowing controlled release of silver ions for anti-microbial action, thus decoupling the absorption function from the anti-microbial function.

Inventive Principle:
Principle #24Intermediary (Mediator)

3Duration of action of moving object

If silver nanoparticles are used to maintain anti-microbial efficacy, then duration of action is improved, but stability and non-cytotoxicity must be maintained

Engineering Contradiction:
Improveanti-microbial efficacy durationVSAvoidstability and non-cytotoxicity
Core Design Contradiction:
Duration of action of moving objectVSStability of the object's composition

Solution Approach 1:

The patent designs the foam matrix to provide continuous, sustained release of polymer-stabilized silver nanoparticles over extended periods. The polymer coating ensures continuous stability of the nanoparticles, preventing aggregation and precipitation, while maintaining their anti-microbial activity throughout the wear period of the dressing.

Inventive Principle:
Principle #20Continuity of useful action

Solution Approach 2:

The polymer stabilizing agent acts as a continuous intermediary that maintains nanoparticle stability and prevents cytotoxic aggregation throughout the duration of use. This intermediary layer ensures that silver remains in a stable, non-cytotoxic form while continuously providing anti-microbial protection.

Inventive Principle:
Principle #24Intermediary (Mediator)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The dressing achieves a 7-day log reduction of 4 or more for bacteria and 2 or more for fungal species, maintaining anti-microbial efficacy for an extended period while being non-cytotoxic, effectively managing exudates and promoting wound healing.

Implementation Method 1

hydrophilic porous substrate

Methodology Applied
Scientific EffectCapillary action: Capillary Action

Implementation Method 2

absorb wound exudates

Methodology Applied
Scientific EffectAdsorption: Adsorption

Implementation Method 3

anti-microbial efficacy

Methodology Applied
Scientific EffectContact killing:

Implementation Method 4

polymer-stabilized silver nanoparticles

Methodology Applied
Scientific EffectSilver ion release: Ionisation

Implementation Method 5

polymer-stabilized silver nanoparticles

Methodology Applied
Scientific EffectPolymer stabilization: Adsorption

Implementation Method 6

stabilized silver nanoparticles in a polymeric matrix

Methodology Applied
Scientific EffectPrevention of aggregation:

Implementation Method 7

retention and release desired therapeutic agents

Methodology Applied
Scientific EffectDiffusion: Diffusion

Implementation Method 8

controlled release

Methodology Applied
Scientific EffectErosion: Erosion

Data Source

PatentUS10537656B2Anti-microbial foams containing polymer-stabilized silver nanoparticles
Publication Date: 2020.01.21 POREX TECHNOLOGIES CORP

AI summary

An absorbent wound dressing comprises a hydrophilic porous substrate and polymer-stabilized silver nanoparticles distributed throughout the porous substrate. The silver nanoparticles have a particle size d50 in the range of about 45 nm to about 85 nm and the silver nanoparticles are present in the substrate in an amount of about 0.16% to about 1.5% by weight of the total weight of the substrate. The wound dressing produces a 7-day log reduction of 4 or more for bacteria in accordance with the Modified AATCC Test Method 100. The wound dressing is also non-cytotoxic in accordance with ISO 10993-5 standard procedure for medical device cytotoxicity assessment.